Rezolute FY26 net loss $77.6M; cash $107.8M; upLIFT positive, sunRIZE under FDA review

Rezolute, Inc.

Cash and investments $107.8M at Jun 30, 2026, down from $167.9M at Jun 30, 2025.
FY2026 net loss $77.6M vs $74.4M FY2025; Q4 net loss $20.5M vs $24.4M year ago.
R&D FY26 $53.8M (down from $61.5M); G&A FY26 $29.2M (up from $18.4M).
upLIFT Phase 3: 7 of 8 enrolled participants met primary endpoint responder criterion; topline results expected before end of 2026.
sunRIZE Phase 3 congenital HI missed primary endpoint; data remains under FDA review; OLE ongoing with improved glycemic control.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.